Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine.
BACKGROUND
Allergic rhinitis is usually treated with oral antihistamines or nasal steroids. Topically active nasal antihistamine is a new treatment modality for allergic rhinitis. The efficacy in comparison to well established topical treatment alternatives is not fully known.


OBJECTIVE
To compare the efficacy of intranasally administered azelastine to budesonide, at their respectively recommended dosage, on the symptoms of perennial rhinitis patients.


METHODS
A placebo-controlled, randomized, parallel group study was conducted to compare the efficacy and tolerability of intranasal budesonide aqueous suspension (256 microg once daily) with azelastine hydrochloride nasal spray (280 microg twice daily (560 microg/day)) and with placebo in the treatment of perennial allergic rhinitis. The 195 patients (with at least a 2-year history of perennial allergic rhinitis) recorded individual nasal symptom scores, the degree of symptom control achieved and any adverse events experienced over a 2-week baseline period and a 6-week treatment period.


RESULTS
Following treatment, the reductions in mean combined and individual nasal symptom scores from baseline values were significantly greater in the budesonide group compared with the placebo group (P < .0001 for all variables except runny nose P = .01). In patients treated with budesonide, there were also significantly larger reductions from baseline values in combined nasal symptom scores (P < .01) and in scores for all individual nasal symptoms (P < or = .05) compared with those treated with azelastine. The reductions from baseline in both combined and individual nasal symptom scores did not differ between azelastine and placebo. The study medications were well tolerated, producing no unexpected or serious treatment-related adverse events.


CONCLUSIONS
A once-daily dose of 256 microg of intranasal budesonide aqueous suspension is significantly more effective at relieving the symptoms of perennial allergic rhinitis compared with a twice daily dose of 280 microg of azelastine nasal spray.
Stern
M A
MA
Midlands Asthma and Allergy Research Association, Leicester General Hospital, United Kingdom.
Wade
A G
AG
Ridout
S M
SM
Cambell
L M
LM
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D019819:Budesonide / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015508:Nasal Obstruction / Q000517:prevention & control; D010793:Phthalazines / Q000008:administration & dosage* / Q000627:therapeutic use; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D010793:Phthalazines; D019819:Budesonide; C020976:azelastine